PhuturdexDrug Pipeline Intelligence

Phuturdex › Drugs › LP-118

Drugs in development · updated 30 October 2026

LP-118: clinical trials and development status

Development codeNot approved in the USNo EMA authorisation

As of 30 October 2026 LP-118 is in 3 active clinical trials (recruiting or ongoing, phases I–III) for 11 diseases. The most advanced phase is I–II.

3Active trials
I–IIMost advanced phase
11Diseases studied

Summary updated every week · data as of 30 October 2026. In Phuturdex you can follow LP-118 and get an email at every change or safety alert.

Sign in free →

Diseases studied

For each disease: the drug’s most advanced phase and active trials, with the reference trial on ClinicalTrials.gov.

DiseaseMost advanced phaseActive trialsReference trial
Precursor lymphoblastic lymphoma/leukemiaI–II3NCT06207123
Acute myeloid leukemiaI1NCT04771572
Chronic lymphocytic leukemiaI1NCT04771572
Hematologic neoplasmI1NCT04771572
LeukemiaI1NCT07614022
Multiple myelomaI1NCT04771572
Myelodysplastic–myeloproliferative diseasesI1NCT04771572
MyelofibrosisI1NCT04771572
NeoplasmI1NCT07614022
Non-Hodgkin lymphomaI1NCT04771572
T-cell prolymphocytic leukemiaI1NCT04771572

Everything on LP-118

In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.

Open in Phuturdex →

Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, is a Phuturdex calculation described on the Method page, not official data.

ItalianoFrançaisDeutsch